A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Pastey MK, Gower TL, Spearman PW, Crowe JE, Graham BS (2000) Nat Med 6: 35-40 Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A (2019) J Virol 93: Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS, Taylor G, Xiong X, Yan X, Portner A, Alymova IV (2009) Antimicrob Agents Chemother 53: 3942-51 Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Crowe JE (1998) Vaccine 16: 1423-32 An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Murphy BR, Hall SL, Kulkarni AB, Crowe JE, Collins PL, Connors M, Karron RA, Chanock RM (1994) Virus Res 32: 13-36
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.